CA3214228A1 - Administration transdermique de cannabidiol - Google Patents

Administration transdermique de cannabidiol Download PDF

Info

Publication number
CA3214228A1
CA3214228A1 CA3214228A CA3214228A CA3214228A1 CA 3214228 A1 CA3214228 A1 CA 3214228A1 CA 3214228 A CA3214228 A CA 3214228A CA 3214228 A CA3214228 A CA 3214228A CA 3214228 A1 CA3214228 A1 CA 3214228A1
Authority
CA
Canada
Prior art keywords
days
once
pain
transdermal
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3214228A
Other languages
English (en)
Inventor
Fotios M. Plakogiannis
Tamanna LATHER
Nisarg MODI
Marina BOROVINSKAYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pike Therapeutics Inc
Original Assignee
Pike Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/227,591 external-priority patent/US12121617B2/en
Application filed by Pike Therapeutics Inc filed Critical Pike Therapeutics Inc
Publication of CA3214228A1 publication Critical patent/CA3214228A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un système d'administration de médicament transdermique comprenant du cannabidiol, ou un sel de cannabidiol seul ou en combinaison avec celui-ci. L'administration transdermique peut fournir une concentration plasmatique de médicament à une vitesse prédéterminée pendant une période de temps prédéterminée avec un régime thérapeutique simplifié par diminution de la fréquence de dosage pour le traitement et/ou la prévention de la douleur et/ou de l'inflammation.
CA3214228A 2021-04-12 2022-04-07 Administration transdermique de cannabidiol Pending CA3214228A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/227,591 2021-04-12
US17/227,591 US12121617B2 (en) 2021-04-12 Transdermal delivery of cannabidiol
PCT/IB2022/053276 WO2022219468A1 (fr) 2021-04-12 2022-04-07 Administration transdermique de cannabidiol

Publications (1)

Publication Number Publication Date
CA3214228A1 true CA3214228A1 (fr) 2022-10-20

Family

ID=83640369

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3214228A Pending CA3214228A1 (fr) 2021-04-12 2022-04-07 Administration transdermique de cannabidiol

Country Status (7)

Country Link
EP (1) EP4322931A1 (fr)
JP (1) JP2024513961A (fr)
CN (1) CN117460503A (fr)
AU (1) AU2022257344A1 (fr)
CA (1) CA3214228A1 (fr)
MX (1) MX2023011948A (fr)
WO (1) WO2022219468A1 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011011514A (es) * 2009-04-28 2011-11-18 Alltranz Inc Formulaciones de canabidiol y metodos para utilizarlas.
US20120202891A1 (en) * 2009-04-29 2012-08-09 University Of Kentucky Research Foundation Cannabinoid-Containing Compositions and Methods for Their Use
SI2473475T1 (sl) * 2009-08-31 2017-10-30 Zynerba Pharmaceuticals, Inc. Uporaba kanabidiolnih predzdravil pri topičnem in transdermalnem dajanju z mikroiglami
BR112020003025A2 (pt) * 2017-08-14 2020-08-04 Zynerba Pharmaceuticals, Inc. métodos de tratamento de osteoartrite com gel transdérmico de canabidiol
US20200289458A1 (en) * 2017-09-22 2020-09-17 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain
AU2020325925A1 (en) * 2019-08-05 2022-03-24 Cs Medica A/S Topical formulations comprising cannabidiol, method of preparing the composition and use thereof
CA3155181A1 (fr) * 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Administration transdermique de cannabidiol
EP4110325A4 (fr) * 2020-04-20 2024-07-03 Pike Therapeutics Inc Formulations pharmaceutiques transdermiques et/ou topiques comprenant du cannabidiol et/ou du tétrahydrocannabinol pour le traitement de la douleur chronique
AU2021302977A1 (en) * 2020-07-01 2023-02-09 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
MX2023000316A (es) * 2020-08-17 2023-02-22 Pike Therapeutics Inc Composiciones farmaceuticas y metodos para el tratamiento de la enfermedad de parkinson.
AU2021393122A1 (en) * 2020-12-03 2023-06-29 Pike Therapeutics Inc. Transdermal pharmaceutical formulations comprising cbd or thc for the treatment of cancer

Also Published As

Publication number Publication date
MX2023011948A (es) 2023-10-17
AU2022257344A1 (en) 2023-10-26
CN117460503A (zh) 2024-01-26
EP4322931A1 (fr) 2024-02-21
JP2024513961A (ja) 2024-03-27
WO2022219468A1 (fr) 2022-10-20

Similar Documents

Publication Publication Date Title
AU2020366147B2 (en) Transdermal delivery of cannabidiol
CA3178878A1 (fr) Formulations pharmaceutiques transdermiques et/ou topiques comprenant du cannabidiol et/ou du tetrahydrocannabinol pour le traitement de la douleur chronique
AU2020361741B2 (en) Transdermal compositions comprising cannabidiol (CBD) for use in the treatment of seizure disorders
US20220047525A1 (en) Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids
US20220000794A1 (en) Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
EP4037663A1 (fr) Administration transdermique de dronabinol
US12121617B2 (en) Transdermal delivery of cannabidiol
CA2578552A1 (fr) Preparations therapeutiques pour administration percutanee de perospirone
CA3214228A1 (fr) Administration transdermique de cannabidiol
US20210259989A1 (en) Transdermal delivery of cannabidiol
US12016829B2 (en) Pharmaceutical composition and method for treating seizure disorders
CA3213953A1 (fr) Composition pharmaceutique et methode de traitement de troubles epileptiques
AU2022260813A1 (en) Transdermal pharmaceutical formulations for the treatment of chronic pain